const content = {
  title: 'Vaccine History',
  sections: [
    {
      content: [
        {
          type: 'timeline',
          content: [
            {
              time: '1881',
              content: "First independently discovered by Louis Pasteur (who called it *microbe septicemique de la salive*) in France from the saliva of a rabies patient, and by George M. Sternberg in the U.S. (who named it *Micrococcus pasteuri*)",
              reference: "https://doi.org/10.1093/clinids/17.5.913"
            },
            {
              time: '1886',
              content: "Renamed 'pneumococcus' for its close association with pneumonia",
              reference: "https://maidenlab.zoo.ox.ac.uk/history-and-biology-istreptococcus-pneumoniaei"
            },
            {
              time: '1911',
              content: "Start of efforts to develop an effective pneumococcal vaccine",
              reference: "https://doi.org/10.1016/S0140-6736(01)56449-1"
            },
            {
              time: '1920',
              content: "Renamed as *Diplococcus pneumoniae* since it was typically observed in pairs",
              reference: "https://doi.org/10.1128%2Fjb.5.3.191-229.1920"
            },
            {
              time: '1928',
              content: "The transformation of life was demonstrated by Frederick Griffith, where harmless pneumococci were turned into a lethal form through the co-inoculation of live harmless pneumococci with heat-killed virulent pneumococci in a mouse; This experiment played a vital role in identifying DNA as the genetic material",
              reference: "https://doi.org/10.1017%2Fs0022172400031879"
            },
            {
              time: '1929',
              content: "The first 32 serotypes were described by Georgia Cooper",
              reference: "https://doi.org/10.1084/jem.49.3.461"
            },
            {
              time: '1939',
              content: "Danish Prince Valdemar died of pneumonia and his failed treatment with serogroup 9 antisera revealed additional diversity in serogroup 9, allowing for the identification of serotype 9V",
              reference: "https://doi.org/10.4049/jimmunol.37.4.359"
            },
            {
              time: '1960s',
              content: "Start of efforts to develop a polyvalent pneumococcal vaccine",
              reference: "https://www.cdc.gov/pinkbook/hcp/table-of-contents/index.html"
            },
            {
              time: '1974',
              content: "Renamed *Streptococcus pneumoniae* for its similarities in chain formation similar to other *Streptococcus spp.*",
              reference: "https://maidenlab.zoo.ox.ac.uk/history-and-biology-istreptococcus-pneumoniaei"
            },
            {
              time: '1977',
              content: "First pneumococcal polysaccharide vaccine licensed in U.S., contained which antigens from 14 serotypes of pneumococci",
              reference: "https://www.cdc.gov/pinkbook/hcp/table-of-contents/index.html"
            },
            {
              time: '1983',
              content: "The 23-valent polysaccharide vaccine was licensed (PPSV23), replacing the 14-valent",
              reference: "https://www.cdc.gov/pinkbook/hcp/table-of-contents/index.html"
            },
            {
              time: '2000',
              content: "First conjugate pneumococcal vaccine licensed in U.S., covering 7 serotypes (PCV7)",
              reference: "https://www.cdc.gov/pinkbook/hcp/table-of-contents/index.html"
            },
            {
              time: '2010',
              content: "Introduction of 13-valent pneumococcal conjugate vaccine (PCV13), covering 6 more serotypes in addition to PCV7",
              reference: "https://www.cdc.gov/pinkbook/hcp/table-of-contents/index.html"
            },
            {
              time: '2020',
              content: "The 100th serotype, 10D, is identified",
              reference: "https://doi.org/10.1128/mBio.00937-20"
            },
            {
              time: '2022',
              content: "PCV15 is licensed for use in children in the US",
              reference: "https://www.cdc.gov/acip/evidence-to-recommendations/pneumo-pcv15-child-etr.html"
            },
            {
              time: '2023',
              content: "PCV20 is licensed for us in children in the US",
              reference: "https://www.cdc.gov/acip/evidence-to-recommendations/pcv20-child-etr.html"
            },
            {
              time: '2024',
              content: "PCV20 is licensed for use in children in Europe",
              reference: "https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-20"
            },
          ]
        },
        {
          type: 'md',
          content: '###### The above timeline is based on the [curation](https://pneumococcalcapsules.github.io/serotypes/) of Chessley B. Blacklock, Daniel M. Weinberger, Stephanie Perniciaro, and Anne L. Wyllie at the Yale School of Public Health'
        },
      ]
    }
  ]
}

export default content
